ArticleInternational journal of clinical and experimental pathology2014
Lin28B is a novel prognostic marker in gastric adenocarcinoma.
Article in International journal of clinical and experimental pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 31 citations in OpenAlex.
- Role of LIN28B in the Regulation of Ribosomal Biogenesis and Lipid Metabolism in Medulloblastoma Brain Cancer Cells.Proteomes · 2025Article
- Expression of Pluripotency Factors OCT4 and LIN28 Correlates with Survival Outcome in Lung Adenocarcinoma.Medicina (Kaunas, Lithuania) · 2024Article
- LOC101929709 promotes gastric cancer progression by aiding LIN28B to stabilize c-MYC mRNA.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2023Article
- The role of LIN28B in tumor progression and metastasis in solid tumor entities.Oncology research · 2023Review
- Review
- Hsa-let-7d-5p Promotes Gastric Cancer Progression by Targeting PRDM5.Journal of oncology · 2022Article
- Integrated analysis of RNA-binding proteins in human colorectal cancer.World journal of surgical oncology · 2020Article
- Potential value of V-domain Ig suppressor of T-cell activation for assessing progn osis in cervical cancer and as a target for therapy.International journal of clinical and experimental pathology · 2020Article
- Knockdown of ROS proto-oncogene 1 inhibits migration and invasion in gastric cancer cells by targeting the PI3K/Akt signaling pathway.OncoTargets and therapy · 2019Article
- Prognostic value of Lin28A and Lin28B in various human malignancies: a systematic review and meta-analysis.Cancer cell international · 2019Article
- Expression of V-domain immunoglobulin suppressor of T cell activation is associated with the advanced stage and presence of lymph node metastasis in ovarian cancer.Oncology letters · 2018Article
- Long non-coding RNA UFC1 promotes gastric cancer progression by regulating miR-498/Lin28b.Journal of experimental & clinical cancer research : CR · 2018Article
- LIN28B enhanced tumorigenesis in an autochthonous KRASOncogene · 2018Article
- PCAF-mediated acetylation of Lin28B increases let-7 biogenesis in lung adenocarcinoma H1299 cells.BMC cancer · 2018Article
- The correlation between LIN28B gene potentially functional variants and Wilms tumor susceptibility in Chinese children.Journal of clinical laboratory analysis · 2018Article
- Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma.Oncotarget · 2017Article
- The LIN28/let-7 Pathway in Cancer.Frontiers in genetics · 2017Review
- Potentially functional polymorphisms in the LIN28B gene contribute to neuroblastoma susceptibility in Chinese children.Journal of cellular and molecular medicine · 2016Article
- Tristetraprolin inhibits gastric cancer progression through suppression of IL-33.Scientific reports · 2016Article
- Lin28: an emerging important oncogene connecting several aspects of cancer.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lin28B, a homologue of Lin28, represses biogenesis of let-7 microRNAs with a role in tumorigenesis and is considered a potential therapeutic target for various human cancers. The aim of the study was to identify the clinical significance of Lin28B in gastric adenocarcinoma (GAC). We examined the expression of Lin28B in 97 human gastric cancer samples with 32 samples of non-dysplastic tissues by immunohistochemistry. In the 97 GAC cases, 42 were with high Lin28B expression. The expression levels of Lin28B proteins in GAC were higher than in corresponding adjacent normal tissues (P=0.001). Significant correlations were noted between Lin28B expression and lymph node status (P=0.005), TNM stage (P < 0.001), tumor invasion (P=0.036), and differentiation (P=0.001) of GAC patients. The Kaplan-Meier estimates showed a negative correlation of overall 5-year survival rate with Lin28B expression where higher expression resulted in poorer prognosis in GAC. In univariate analysis, lymph node metastasis, TNM stage, serosal invasion, Lin28B expression as well as differentiation grade could predict the prognosis of GAC patients (P=0.002, P < 0.001, P=0.003, P < 0.001, P=0.001, respectively). Multivariate analysis revealed that the expression level of Lin28B (P < 0.001), TNM stage (P < 0.001) as well as differentiation grade (P < 0.001) were the three potential independent prognostic factors in our study [Hazard ratio (HR)=2.108 and P=0.017, HR=1.994 and P=0.018, HR=1.939 and P=0.046, respectively]. Our findings point to the prognostic role of Lin28B in GAC, and indicate Lin28B as a potential therapeutic target of GAC patients.
Indexed as
Identifiers
25197381PMC4152071W147039028What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.